Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
GlaxoSmithKline ( (GB:GSK) ) has provided an announcement.
GSK plc has announced provisional dividend dates for the year 2026, outlining key dates for ordinary shares and American Depositary Shares. These dates are subject to change and provide stakeholders with a timeline for dividend-related activities, reflecting GSK’s commitment to maintaining transparency and shareholder engagement.
The most recent analyst rating on (GB:GSK) stock is a Sell with a £15.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s strong financial performance and positive earnings call sentiment are the most significant factors driving the stock score. The company’s robust growth in specialty medicines and successful R&D efforts contribute positively. Technical analysis supports a bullish outlook, while valuation remains reasonable with an attractive dividend yield. Challenges in the U.S. vaccines market and clinical trial delays are noted but do not significantly detract from the overall positive outlook.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
GSK plc is a leading global healthcare company operating in the pharmaceutical industry. It focuses on the development and manufacturing of vaccines, medicines, and consumer healthcare products, aiming to improve the quality of human life by enabling people to do more, feel better, and live longer.
Average Trading Volume: 8,291,513
Technical Sentiment Signal: Buy
Current Market Cap: £71.07B
For detailed information about GSK stock, go to TipRanks’ Stock Analysis page.